Meridian Meadows: No Consent for Anxiety Drug - ID
Federal inspectors found Meridian Meadows Transitional Care failed to obtain informed consent before administering lorazepam to Resident #5, who was admitted with congestive heart failure and acute kidney disease. The facility's chief registered nurse confirmed during the April inspection that no consent form had been signed.
Lorazepam is a controlled substance that can cause drowsiness, confusion, and breathing problems, particularly dangerous for elderly patients with multiple medical conditions. The resident received orders for the drug both for general anxiety and specifically for terminal agitation related to her end-of-life care.
The medication orders were extensive. Resident #5 could receive 0.5 mL of lorazepam oral concentrate every eight hours as needed for anxiety. A separate order allowed the same dosage every eight hours for terminal agitation, authorized for 180 days.
No documentation existed showing the resident or her representative had been informed about what lorazepam would do, why doctors ordered it, or what side effects to expect. The consent gap meant family members making medical decisions lacked crucial information about a powerful medication being given to their dying relative.
Terminal agitation affects many patients in their final days, causing restlessness, confusion, and distress. Lorazepam can provide relief but also carries risks of oversedation and respiratory depression in frail patients. These competing factors make informed consent particularly important for families weighing comfort versus potential complications.
The inspection occurred on April 3, nearly two months after the resident's admission. By then, staff had been administering the medication under orders that assumed proper consent procedures had been followed.
When inspectors reviewed six residents' records for informed consent practices, Resident #5's case stood out as the only clear violation. The other five residents had appropriate documentation showing they or their representatives understood their prescribed treatments.
The facility's chief registered nurse acknowledged the problem during interviews with federal inspectors. She confirmed that neither the resident nor her representative had signed consent forms documenting their understanding of lorazepam's risks and benefits before the medication became an active order.
This type of consent failure creates multiple problems beyond the immediate regulatory violation. Family members may discover their relative received medications they would have refused if properly informed. Patients themselves lose the opportunity to participate in decisions about their own care, even when facing terminal illness.
The timing makes the violation more concerning. Palliative care patients and their families often spend considerable time discussing treatment goals and medication choices. These conversations help ensure that interventions align with the patient's wishes for comfort, pain management, and quality of life in their remaining time.
Lorazepam orders for terminal agitation suggest medical staff recognized the resident was approaching end of life. Yet the same staff failed to complete basic consent procedures that would have involved her family in understanding this significant medication decision.
Federal regulations require facilities to inform residents in advance about their care and treatment, including risks and benefits. The rule exists specifically to prevent situations like Resident #5 experienced, where powerful medications are administered without proper patient or family understanding.
The inspection classified this as minimal harm with potential for actual harm. While the resident may not have suffered immediate injury from receiving lorazepam, the lack of informed consent created risks of miscommunication and adverse effects that proper procedures would have prevented.
Meridian Meadows must now develop a plan to correct the deficiency and demonstrate that all residents receive appropriate informed consent before starting new medications. The facility has not yet submitted its correction plan to state survey officials.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Meridian Meadows Transitional Care from 2026-04-03 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: June 20, 2026 · Our methodology
Meridian Meadows Transitional Care in Meridian, ID was cited for violations during a health inspection on April 3, 2026.
The facility's chief registered nurse confirmed during the April inspection that no consent form had been signed.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.